Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Long-Term Debt Repayments (2019 - 2024)

Abvc Biopharma (ABVC) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $147892.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Long-Term Debt Repayments changed N/A year-over-year to $147892.0, compared with a TTM value of $1.1 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $277284.0, down 15.21% over the prior year.
  • Long-Term Debt Repayments was $147892.0 for Q4 2024 at Abvc Biopharma, down from $1.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.0 million in Q1 2023 and bottomed at $121.0 in Q3 2020.
  • Average Long-Term Debt Repayments over 4 years is $245458.7, with a median of $147892.0 recorded in 2024.
  • Peak annual rise in Long-Term Debt Repayments hit 2716.28% in 2020, while the deepest fall reached 99.05% in 2020.
  • Year by year, Long-Term Debt Repayments stood at $121.0 in 2020, then surged by 46871.9% to $56836.0 in 2021, then skyrocketed by 1659.45% to $1.0 million in 2023, then crashed by 85.21% to $147892.0 in 2024.
  • Business Quant data shows Long-Term Debt Repayments for ABVC at $147892.0 in Q4 2024, $1.0 million in Q1 2023, and $56836.0 in Q2 2021.